Protox Therapeutics Inc. (“Protox”, TSX: PRX), a developer of innovative products for the treatment of urological diseases, today announced that it has entered into a US $15 million loan agreement ...

Protox Therapeutics Signs $75 Million License Agreement with Kissei Pharmaceutical Co., Ltd. for Commercialization of PRX302 in Japan for BPH and Prostate Disease VANCOUVER, April 29 /CNW/ - Protox ...

VANCOUVER, Oct. 8 /CNW/ - Protox Therapeutics Inc. (TSX: PRX - News), a leader in the development of receptor targeted fusion proteins, today announced positive 12 month data from its Phase 1 study of ...

About Protox Protox Therapeutics is a developer of innovative products for the treatment of urological diseases. Protox's lead program, PRX302 (PORxin), achieved positive results from its Phase 2b ...

Protox Therapeutics Inc. is appointing William Rohn and Amit Sobti to the company’s board of directors. “We are delighted to welcome Bill and Amit to help guide Protox through the exciting phase of ...

Shareholders of Vancouver-based Protox Therapeutics Inc. (TSX:PRX) have approved multi-stage financing that could see a global private equity firm become the company’s majority shareholder. Under the ...

PRX302 is currently in North American Phase II evaluation as PSA-activated pore-punching prodrug. Kissei Pharamaceutical is paying Protox Therapeutics $3 million up front for exclusive Japanese rights ...

VANCOUVER – Protox Therapeutics Inc. (TSX:PRX), a developer of drugs to treat urological diseases, said Monday it has entered into a US $15 million loan agreement with a U.S. lender to help the ...